deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00813163

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer

Sponsor: PharmaEngine

Conditions Pancreatic Neoplasms
Interventions PEP02
Updated 10 times since 2017 Last updated: Aug 27, 2019 Started: Jan 31, 2009 Primary completion: Dec 31, 2010 Completion: Jul 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pancreatic Neoplasms, this trial is completed. The trial is conducted by PharmaEngine and has accumulated 10 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Oct 2019 · 16 months · monthly snapshotCompleted~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshotCompleted~Dec 2025 – present · 9 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  2. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE2

  3. Jun 2018 — Oct 2019 [monthly]

    Completed PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • PharmaEngine
Data source: PharmaEngine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations